KR101768946B1 - 프롤린 유도체 - Google Patents
프롤린 유도체 Download PDFInfo
- Publication number
- KR101768946B1 KR101768946B1 KR1020127014885A KR20127014885A KR101768946B1 KR 101768946 B1 KR101768946 B1 KR 101768946B1 KR 1020127014885 A KR1020127014885 A KR 1020127014885A KR 20127014885 A KR20127014885 A KR 20127014885A KR 101768946 B1 KR101768946 B1 KR 101768946B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- compounds
- mmol
- preparation
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ZOOSILUVXHVRJE-UHFFFAOYSA-N O=C(C1CC1)Cl Chemical compound O=C(C1CC1)Cl ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 2
- 0 OC(*c1ccccc1)=O Chemical compound OC(*c1ccccc1)=O 0.000 description 2
- XBSBLUNEDZIZDQ-FGZHOGPDSA-N C(C1)CN[C@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c2cnc([C@@H]3NCCC3)[s]2)[s]1 Chemical compound C(C1)CN[C@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c2cnc([C@@H]3NCCC3)[s]2)[s]1 XBSBLUNEDZIZDQ-FGZHOGPDSA-N 0.000 description 1
- ZODOJONZPKZMBC-ORAKWCKGSA-N CC(C(N(CCC1)C1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c2cnc([C@@H](CCC3)N3C([C@@H](c3ccccc3)NC(C3CC3)=O)O)[s]2)[s]1)=O)(c1ccccc1)NC(C1CC1)=O Chemical compound CC(C(N(CCC1)C1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c2cnc([C@@H](CCC3)N3C([C@@H](c3ccccc3)NC(C3CC3)=O)O)[s]2)[s]1)=O)(c1ccccc1)NC(C1CC1)=O ZODOJONZPKZMBC-ORAKWCKGSA-N 0.000 description 1
- GEBXFMFXVCRYMI-XBVPFSNISA-N C[C@@H](C(N(CCC1)[C@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c2cnc([C@@H](CCC3)N3C(Cc3ccccc3)=O)[s]2)[s]1)=O)c1ccccc1 Chemical compound C[C@@H](C(N(CCC1)[C@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c2cnc([C@@H](CCC3)N3C(Cc3ccccc3)=O)[s]2)[s]1)=O)c1ccccc1 GEBXFMFXVCRYMI-XBVPFSNISA-N 0.000 description 1
- OOGNGRKAKOFVOW-AEQXKOAMSA-N NC(C(N(CCC1)C1c1ncc(-c(cc2)ccc2-c(cc2)ccc2C2=CNC([C@@H](CCC3)N3C([C@H](c3ccccc3)NC(C3CC3)=O)=O)S2)[s]1)O)c(cccc1)c1/[O]=C/C1CC1 Chemical compound NC(C(N(CCC1)C1c1ncc(-c(cc2)ccc2-c(cc2)ccc2C2=CNC([C@@H](CCC3)N3C([C@H](c3ccccc3)NC(C3CC3)=O)=O)S2)[s]1)O)c(cccc1)c1/[O]=C/C1CC1 OOGNGRKAKOFVOW-AEQXKOAMSA-N 0.000 description 1
- AWFLTCFDBJCFBI-UHFFFAOYSA-N OC1C(Cc2ccccc2)C1 Chemical compound OC1C(Cc2ccccc2)C1 AWFLTCFDBJCFBI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26658409P | 2009-12-04 | 2009-12-04 | |
| US61/266,584 | 2009-12-04 | ||
| PCT/US2010/058672 WO2011068941A2 (en) | 2009-12-04 | 2010-12-02 | Proline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120102690A KR20120102690A (ko) | 2012-09-18 |
| KR101768946B1 true KR101768946B1 (ko) | 2017-08-17 |
Family
ID=44082623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127014885A Expired - Fee Related KR101768946B1 (ko) | 2009-12-04 | 2010-12-02 | 프롤린 유도체 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8415482B2 (https=) |
| EP (1) | EP2507232B1 (https=) |
| JP (1) | JP5753185B2 (https=) |
| KR (1) | KR101768946B1 (https=) |
| CN (1) | CN102482269B (https=) |
| AU (1) | AU2010325980B2 (https=) |
| CA (1) | CA2781140C (https=) |
| MY (1) | MY179840A (https=) |
| TW (1) | TWI429645B (https=) |
| WO (1) | WO2011068941A2 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2367823A1 (en) | 2008-12-23 | 2011-09-28 | Abbott Laboratories | Anti-viral compounds |
| CA2740193A1 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102459165B (zh) | 2009-04-15 | 2015-09-02 | Abbvie公司 | 抗病毒化合物 |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| UA118080C2 (uk) * | 2009-06-11 | 2018-11-26 | Еббві Айрленд Анлімітед Компані | Противірусні сполуки |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN105228619B (zh) * | 2012-11-08 | 2019-05-24 | 财团法人国家卫生研究院 | 治疗c型肝炎病毒感染的医药组合物 |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| CN104774194B (zh) * | 2014-01-09 | 2018-01-30 | 正大天晴药业集团股份有限公司 | 氘代的丙型肝炎病毒抑制剂 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| AU2021230289A1 (en) | 2020-03-03 | 2022-09-29 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| JP2024534127A (ja) | 2021-08-25 | 2024-09-18 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| CN113861061A (zh) * | 2021-10-25 | 2021-12-31 | 成都市科隆化学品有限公司 | 一种不含无机铵盐的氨基酸酰胺盐酸盐及其合成方法 |
| AU2023366352A1 (en) * | 2022-10-28 | 2025-05-08 | Assistance Publique – Hopitaux De Paris (Aphp) | New inhibitors of phosphatidylinositol 3-kinase |
| CN117105928B (zh) * | 2023-08-22 | 2024-03-26 | 上海蓝木化工有限公司 | 一种蛋白酶抑制剂及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008021927A2 (en) * | 2006-08-11 | 2008-02-21 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US20080311075A1 (en) | 2007-05-17 | 2008-12-18 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20090043107A1 (en) | 2007-08-08 | 2009-02-12 | Bristol-Myers Squibb Company | Process for Synthesizing Compounds Useful for Treating Hepatitis C |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050043545A1 (en) * | 2001-11-02 | 2005-02-24 | Gianpalol Bravi | 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PT3309157T (pt) * | 2009-05-13 | 2019-12-02 | Gilead Pharmasset Llc | Compostos antivirais |
| US8138215B2 (en) * | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2010
- 2010-12-02 EP EP10835108.1A patent/EP2507232B1/en not_active Not-in-force
- 2010-12-02 JP JP2012542178A patent/JP5753185B2/ja not_active Expired - Fee Related
- 2010-12-02 AU AU2010325980A patent/AU2010325980B2/en not_active Ceased
- 2010-12-02 KR KR1020127014885A patent/KR101768946B1/ko not_active Expired - Fee Related
- 2010-12-02 CA CA2781140A patent/CA2781140C/en not_active Expired - Fee Related
- 2010-12-02 WO PCT/US2010/058672 patent/WO2011068941A2/en not_active Ceased
- 2010-12-02 TW TW099141900A patent/TWI429645B/zh not_active IP Right Cessation
- 2010-12-02 CN CN201080002506.6A patent/CN102482269B/zh not_active Expired - Fee Related
- 2010-12-02 US US12/958,734 patent/US8415482B2/en not_active Expired - Fee Related
- 2010-12-02 MY MYPI2012002245A patent/MY179840A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008021927A2 (en) * | 2006-08-11 | 2008-02-21 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US20080050336A1 (en) | 2006-08-11 | 2008-02-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20080311075A1 (en) | 2007-05-17 | 2008-12-18 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20090043107A1 (en) | 2007-08-08 | 2009-02-12 | Bristol-Myers Squibb Company | Process for Synthesizing Compounds Useful for Treating Hepatitis C |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110136799A1 (en) | 2011-06-09 |
| JP5753185B2 (ja) | 2015-07-22 |
| TW201120035A (en) | 2011-06-16 |
| EP2507232B1 (en) | 2019-03-20 |
| AU2010325980A1 (en) | 2012-06-14 |
| TWI429645B (en) | 2014-03-11 |
| JP2013512915A (ja) | 2013-04-18 |
| CN102482269A (zh) | 2012-05-30 |
| CN102482269B (zh) | 2015-07-29 |
| EP2507232A2 (en) | 2012-10-10 |
| MY179840A (en) | 2020-11-18 |
| WO2011068941A3 (en) | 2011-11-17 |
| US8415482B2 (en) | 2013-04-09 |
| EP2507232A4 (en) | 2013-12-18 |
| AU2010325980B2 (en) | 2016-04-07 |
| HK1171439A1 (zh) | 2013-03-28 |
| CA2781140C (en) | 2017-10-24 |
| WO2011068941A2 (en) | 2011-06-09 |
| CA2781140A1 (en) | 2011-06-09 |
| KR20120102690A (ko) | 2012-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101768946B1 (ko) | 프롤린 유도체 | |
| RU2660421C2 (ru) | Бензиламиновые производные | |
| ES2384309T3 (es) | Derivados de ácido carboxílico sustituidos de manera oxo-heterocíclica y su uso | |
| DE60124718T2 (de) | Inhibitoren für virale polymerase | |
| RU2099331C1 (ru) | N-замещенные гетероциклические производные или их соли, промежуточные производные пиримидина и имидазолина и фармацевтическая композиция на основе замещенных гетероциклических производных | |
| CA2630714C (en) | S1p receptor modulating compounds and use thereof | |
| CA2637024C (en) | Substituted imidazole derivatives, compositions, and methods of use as ptpase inhibitors | |
| SK48499A3 (en) | Heteroaryl succinamides and their use as metalloproteinase inhibitors | |
| JP4075064B2 (ja) | ４，４−ジフルオロ−１，２，３，４−テトラヒドロ−５ｈ−１−ベンゾアゼピン誘導体又はその塩 | |
| WO2011153588A1 (en) | Viral polymerase inhibitors | |
| KR20090033912A (ko) | 화학적 화합물 | |
| JP2002308875A (ja) | エンドセリンの活性を調節するスルホンアミドおよびそれらの誘導体 | |
| MXPA05004435A (es) | Derivados de 1-acil-pirrolidina para el tratamiento de infecciones virales. | |
| KR100714585B1 (ko) | 약학적인 활성 피롤리딘 유도체 | |
| US20070082932A1 (en) | Pyrrolidine compounds | |
| JP4943858B2 (ja) | 芳香族アミド誘導体、それを含有する医薬組成物およびそれらの医薬用途 | |
| JP4629037B2 (ja) | 炎症疾患治療のためのブラジキニンｂ１受容体アンタゴニストとしての４−ブロモ−５−（２−クロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸（１−（アミノカルボニル）エト−１−イル）アミド誘導体および関連化合物 | |
| JPH03101648A (ja) | ペプチジルアミノジオール系レニン抑制剤 | |
| KR20040030678A (ko) | 피롤리딘 옥사디아졸 및 티아디아졸 유도체 | |
| AU2006264049B2 (en) | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | |
| WO2009038411A2 (en) | Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety | |
| HK1171439B (en) | Proline derivatives | |
| JPH08501566A (ja) | レニン阻害剤としてのｎ−（ヒドロキシエチル）ブタンジアミド誘導体 | |
| US6624313B2 (en) | Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists | |
| WO2025114399A1 (en) | Flavivirus inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| X091 | Application refused [patent] | ||
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20200811 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20200811 |